HK1250624A1 - 用於治療心血管障礙的方法 - Google Patents
用於治療心血管障礙的方法Info
- Publication number
- HK1250624A1 HK1250624A1 HK18109990.1A HK18109990A HK1250624A1 HK 1250624 A1 HK1250624 A1 HK 1250624A1 HK 18109990 A HK18109990 A HK 18109990A HK 1250624 A1 HK1250624 A1 HK 1250624A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- treatment
- methods
- cardiovascular disorders
- cardiovascular
- disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1506228.4A GB201506228D0 (en) | 2015-04-13 | 2015-04-13 | Methods For The Treatment Of Cardivascular Disorders |
GBGB1507109.5A GB201507109D0 (en) | 2015-04-27 | 2015-04-27 | Methods for the treatment of cardiovascular disorders |
GBGB1513344.0A GB201513344D0 (en) | 2015-07-29 | 2015-07-29 | Methods for the treatment of Cardiovascular disorders |
GBGB1513991.8A GB201513991D0 (en) | 2015-08-07 | 2015-08-07 | Methods for the treatment of cardiovascular disorders |
GBGB1521542.9A GB201521542D0 (en) | 2015-12-07 | 2015-12-07 | Methods for the treatment of cardiovascular disorders |
PCT/EP2016/057103 WO2016165952A1 (en) | 2015-04-13 | 2016-03-31 | Methods for the treatment of cardiovascular disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1250624A1 true HK1250624A1 (zh) | 2019-01-11 |
Family
ID=55640760
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18109990.1A HK1250624A1 (zh) | 2015-04-13 | 2018-08-02 | 用於治療心血管障礙的方法 |
Country Status (18)
Country | Link |
---|---|
US (1) | US10376520B2 (zh) |
EP (1) | EP3283114B1 (zh) |
JP (1) | JP6898249B2 (zh) |
KR (1) | KR20170134751A (zh) |
CN (1) | CN107438609B (zh) |
AU (1) | AU2016248727B2 (zh) |
BR (1) | BR112017021589B1 (zh) |
CA (1) | CA2982629C (zh) |
EA (1) | EA037911B1 (zh) |
ES (1) | ES2959612T3 (zh) |
HK (1) | HK1250624A1 (zh) |
HR (1) | HRP20231192T1 (zh) |
HU (1) | HUE063820T2 (zh) |
MX (1) | MX2017013103A (zh) |
PL (1) | PL3283114T3 (zh) |
RS (1) | RS64677B1 (zh) |
SG (1) | SG11201708198SA (zh) |
WO (1) | WO2016165952A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3043396A1 (en) | 2016-11-10 | 2018-05-17 | Galapagos Nv | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI462920B (zh) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
JO3030B1 (ar) * | 2009-06-26 | 2016-09-05 | Galapagos Nv | مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات |
JP6238975B2 (ja) | 2012-06-22 | 2017-11-29 | ガラパゴス・ナムローゼ・フェンノートシャップGalapagos N.V. | 炎症の治療に使用するためのアミノトリアゾロピリジン及びその医薬組成物 |
GB201402071D0 (en) * | 2014-02-07 | 2014-03-26 | Galapagos Nv | Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
US20170141833A1 (en) * | 2015-01-23 | 2017-05-18 | Samsung Electronics Co., Ltd. | Method and device for supporting data communication in wireless communication system |
-
2016
- 2016-03-31 AU AU2016248727A patent/AU2016248727B2/en active Active
- 2016-03-31 MX MX2017013103A patent/MX2017013103A/es unknown
- 2016-03-31 KR KR1020177032860A patent/KR20170134751A/ko not_active Application Discontinuation
- 2016-03-31 JP JP2017553315A patent/JP6898249B2/ja active Active
- 2016-03-31 CN CN201680021723.7A patent/CN107438609B/zh active Active
- 2016-03-31 US US15/566,002 patent/US10376520B2/en active Active
- 2016-03-31 PL PL16712378.5T patent/PL3283114T3/pl unknown
- 2016-03-31 CA CA2982629A patent/CA2982629C/en active Active
- 2016-03-31 EP EP16712378.5A patent/EP3283114B1/en active Active
- 2016-03-31 EA EA201792265A patent/EA037911B1/ru unknown
- 2016-03-31 SG SG11201708198SA patent/SG11201708198SA/en unknown
- 2016-03-31 RS RS20230922A patent/RS64677B1/sr unknown
- 2016-03-31 WO PCT/EP2016/057103 patent/WO2016165952A1/en active Application Filing
- 2016-03-31 ES ES16712378T patent/ES2959612T3/es active Active
- 2016-03-31 HU HUE16712378A patent/HUE063820T2/hu unknown
- 2016-03-31 BR BR112017021589-6A patent/BR112017021589B1/pt active IP Right Grant
- 2016-03-31 HR HRP20231192TT patent/HRP20231192T1/hr unknown
-
2018
- 2018-08-02 HK HK18109990.1A patent/HK1250624A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
JP6898249B2 (ja) | 2021-07-07 |
NZ735883A (en) | 2021-11-26 |
RS64677B1 (sr) | 2023-11-30 |
KR20170134751A (ko) | 2017-12-06 |
US20180185377A1 (en) | 2018-07-05 |
HRP20231192T1 (hr) | 2024-02-16 |
EP3283114B1 (en) | 2023-09-06 |
MX2017013103A (es) | 2018-01-30 |
EP3283114A1 (en) | 2018-02-21 |
BR112017021589B1 (pt) | 2023-05-09 |
CA2982629A1 (en) | 2016-10-20 |
SG11201708198SA (en) | 2017-11-29 |
BR112017021589A2 (pt) | 2018-07-03 |
CA2982629C (en) | 2023-09-05 |
CN107438609A (zh) | 2017-12-05 |
PL3283114T3 (pl) | 2024-01-03 |
HUE063820T2 (hu) | 2024-02-28 |
CN107438609B (zh) | 2020-10-09 |
JP2018511618A (ja) | 2018-04-26 |
EP3283114C0 (en) | 2023-09-06 |
EA037911B1 (ru) | 2021-06-04 |
US10376520B2 (en) | 2019-08-13 |
AU2016248727A1 (en) | 2017-10-19 |
ES2959612T3 (es) | 2024-02-27 |
WO2016165952A1 (en) | 2016-10-20 |
EA201792265A1 (ru) | 2018-04-30 |
AU2016248727B2 (en) | 2021-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL285151A (en) | Methods for the treatment of fgf21-related disorders | |
HK1259458A1 (zh) | 用於治療心血管疾病的吉卡賓組合 | |
IL279627A (en) | A method for treating depression | |
IL279308A (en) | Methods for the treatment of heptidine-mediated disorders | |
HK1252996A1 (zh) | 用於治療癲癇的方法 | |
HK1232220A1 (zh) | 用於治療心血管疾病的 -苄基異喹啉衍生物 | |
SG11201708181RA (en) | Methods for the treatment of inflammatory disorders | |
HK1247558A1 (zh) | 塞內可瑞偉洛克(cenicriviroc)用於治療纖維化 | |
SG11201609522TA (en) | Methods for treating cardiovascular diseases | |
GB201607388D0 (en) | Treatment of impulsivity-related disorders | |
PL3484475T3 (pl) | 1-Metylonikotynamid do leczenia choroby układu krążenia | |
HK1250624A1 (zh) | 用於治療心血管障礙的方法 | |
GB201521542D0 (en) | Methods for the treatment of cardiovascular disorders | |
GB201513991D0 (en) | Methods for the treatment of cardiovascular disorders | |
GB201513344D0 (en) | Methods for the treatment of Cardiovascular disorders | |
GB201507109D0 (en) | Methods for the treatment of cardiovascular disorders | |
GB201521543D0 (en) | Methods for the treatment of inflammatory disorders | |
GB201506228D0 (en) | Methods For The Treatment Of Cardivascular Disorders | |
GB201513993D0 (en) | Methods for the treatment of inflammatory disorders | |
GB201513345D0 (en) | Methods for the treatment of Inflammatory disorders | |
GB201507113D0 (en) | Methods for the treatment of inflammatory disorders | |
GB201506419D0 (en) | Methods for the treatment of inflammatory disorders | |
GB201506229D0 (en) | Methods For the Treatment Of Inflammatory Disorders | |
GB201602784D0 (en) | New treatment of CFTR-related disorders | |
GB201516418D0 (en) | Treatment of acute inflammatory disorders |